Cargando…

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer

Late stage epithelial ovarian cancer has a dismal prognosis. Identification of pharmacogenomic markers (i.e. polymorphisms) to stratify patients to optimize individual therapy is of paramount importance. We here report the retrospective analysis of polymorphisms in 5 genes (ATM, ATR, Chk1, Chk2 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guffanti, F., Fruscio, R., Rulli, E., Damia, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131275/ https://www.ncbi.nlm.nih.gov/pubmed/27905519 http://dx.doi.org/10.1038/srep38142

Ejemplares similares

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy
por: Ricci, Francesca, et al.
Publicado: (2016)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
por: Bouberhan, Sara, et al.
Publicado: (2023)

Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer
por: Chang-Claude, J, et al.
Publicado: (2009)

DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
por: Ovejero-Sánchez, María, et al.
Publicado: (2023)

Platinum Resistance in Ovarian Cancer: Role of DNA Repair
por: Damia, Giovanna, et al.
Publicado: (2019)

Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease
por: Lovell, Mark A., et al.
Publicado: (2007)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes
por: Chiang, Ying-Cheng, et al.
Publicado: (2021)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Therapeutic Targeting of DNA Damage Response in Cancer
por: Choi, Wonyoung, et al.
Publicado: (2022)

Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2015)

DNA Damage Response Gene-Based Subtypes Associated With Clinical Outcomes in Early-Stage Lung Adenocarcinoma
por: Zhao, Yang, et al.
Publicado: (2022)

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
por: Sanij, Elaine, et al.
Publicado: (2020)

The DNA damage response activates HPV16 late gene expression at the level of RNA processing
por: Nilsson, Kersti, et al.
Publicado: (2018)

Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

Strategies for targeting the DNA damage response for cancer therapeutics
por: Zhang, Dan, et al.
Publicado: (2012)

DNA damaging agents in ovarian cancer
por: Barretina-Ginesta, Maria-Pilar
Publicado: (2020)

Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers
por: Lee, Yoo-Kyung, et al.
Publicado: (2015)

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer
por: Kubelac, Paul, et al.
Publicado: (2020)

Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma
por: Wong, Oscar G. W., et al.
Publicado: (2021)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Association between DNA Damage Response and Repair Genes and Risk of Invasive Serous Ovarian Cancer
por: Schildkraut, Joellen M., et al.
Publicado: (2010)

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
por: Affatato, Roberta, et al.
Publicado: (2020)

Predictive modeling of gene expression regulation
por: Regondi, Chiara, et al.
Publicado: (2021)

AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation
por: Cerra, Christian, et al.
Publicado: (2016)

Use of staging for sex cord stromal tumours
por: Negri, Serena, et al.
Publicado: (2022)

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response
por: Yuan, Sheng, et al.
Publicado: (2023)

Impact of the DNA Damage Response on Human Papillomavirus Chromatin
por: Gautam, Dipendra, et al.
Publicado: (2016)

DNA damage response and prostate cancer: defects, regulation and therapeutic implications
por: Karanika, Styliani, et al.
Publicado: (2014)

The Intersection of DNA Damage Response and Ferroptosis—A Rationale for Combination Therapeutics
por: Chen, Po-Han, et al.
Publicado: (2020)

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
por: George, Sally L, et al.
Publicado: (2020)

Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment
por: Maresca, Luisa, et al.
Publicado: (2022)

Impact of Single Nucleotide Polymorphisms of Base Excision Repair Genes on DNA Damage and Efficiency of DNA Repair in Recurrent Depression Disorder
por: Czarny, Piotr, et al.
Publicado: (2016)

DNA Damage Stress Response and Follicle Activation: Signaling Routes of Mammalian Ovarian Reserve
por: Gonfloni, Stefania, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fq09neojcak9j7oisalp0efk7a